Amneal Pharmaceuticals, Inc.
AMRX
Classement en actions
#2938
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Prix de l'action
$19.75
Capitalisation boursière
$6.31B
Changement (1 jour)
2.00%
Changement (1 an)
92.84%
Pays
US
Échange Amneal Pharmaceuticals, Inc. (AMRX)
Catégorie
Healthcare
Nombre d'actions en circulation pour Amneal Pharmaceuticals, Inc. (AMRX)
Nombre d'actions en circulation au June 2026: 319.20M
Selon les derniers rapports financiers et le cours de l'action de Amneal Pharmaceuticals, Inc., le nombre actuel d'actions en circulation est de 319.20M. À la fin de December 2023, l'entreprise avait 174.99M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Amneal Pharmaceuticals, Inc. (AMRX) de 2014 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 319.20M | 3.31% |
| 2024 | 308.98M | 76.57% |
| 2023 | 174.99M | 15.93% |
| 2022 | 150.94M | 1.36% |
| 2021 | 148.92M | -0.24% |
| 2020 | 149.28M | 13.01% |
| 2019 | 132.09M | 3.80% |
| 2018 | 127.25M | 10.79% |
| 2017 | 114.86M | -39.23% |
| 2016 | 189.00M | 0.00% |
| 2015 | 189.00M | 0.00% |
| 2014 | 189.00M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 651.67% |
IN
|
